Sugi Predict

Sugi Predict / Compounds / SCHEMBL4543061

SCHEMBL4543061

SCHEMBL4543061

Nc1cc2c([nH]c3ccccc32)c(-c2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ HTR2B P41595 2/20 0.56
▸ HTR5A P47898 2/20 0.56
▸ TDO2 P48775 2/20 0.56
▸ NQO2 P16083 1/20 0.50
▸ MGAM O43451 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ HDAC1 Q13547 1/20 0.46
▸ SMARCA2 P51531 1/20 0.46
▸ SMARCA4 P51532 1/20 0.46
▸ PBRM1 Q86U86 1/20 0.46
▸ CA5A P35218 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23500446 0.88 MEN1 (0.52) MEN1KMT2AHTR2BHTR5ATDO2
SCHEMBL31327501 0.88 MEN1 (0.52) MEN1KMT2AHTR2BHTR5ATDO2
SCHEMBL31327502 0.85 HDAC1 (0.48) MEN1KMT2AHTR2BHTR5ATDO2
SCHEMBL23500517 0.85 HDAC1 (0.56) MEN1KMT2AMGAMHDAC1
SCHEMBL31327498 0.85 HDAC1 (0.56) MEN1KMT2AMGAMHDAC1
SCHEMBL25412800 0.83 IDO1 (0.65) MEN1KMT2AMGAMALDH1A1HPGD
SCHEMBL23500532 0.83 HDAC3 (0.54) MEN1KMT2AMGAMKDM4EALDH1A1
SCHEMBL31327506 0.83 HDAC3 (0.54) MEN1KMT2AMGAMKDM4EALDH1A1
Ammonia Solution, Strong SCHEMBL28650410 0.83 HTR2B (0.58) MEN1KMT2AHTR2BHTR5ATDO2
SCHEMBL31327512 0.82 MGAM (0.48) MEN1KMT2AMGAMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104628723-B A kind of banisterine benzoyl urea compound and its preparation method and application SOUTH CHINA AGRICULTURAL UNIVERSITY (CN) 2016-06-01 — — CN claimed
CN-104628723-A Banisterine benzoyl urea compounds and preparation method and application thereof UNIV SOUTH CHINA AGRICULT 2015-05-20 — — CN claimed
US-12319698-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2025-06-03 — — US disclosed
CN-112585132-B Proteasome activity enhancing compounds 优曼尼蒂公司 2025-02-28 — — CN disclosed
US-11958873-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2024-04-16 — — US disclosed
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Kineta, Inc. 2023-08-03 — — US disclosed
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS YUMANITY THERAPEUTICS, INC. 2023-06-15 — — US disclosed
US-11560385-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2023-01-24 — — US disclosed
US-20220298181-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS INC (US) 2022-09-22 — — US disclosed
US-11242361-B2 Proteasome activity enhancing compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2022-02-08 — — US disclosed
EP-3814338-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Proteostasis Therapeutics, Inc. (US) 2021-05-05 — — EP disclosed
US-20160333031-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. 2016-11-17 — — US disclosed
CN-104628723-B A kind of banisterine benzoyl urea compound and its preparation method and application SOUTH CHINA AGRICULTURAL UNIVERSITY (CN) 2016-06-01 — — CN disclosed
WO-2015073528-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-05-21 — — WO disclosed
CN-104628723-A Banisterine benzoyl urea compounds and preparation method and application thereof UNIV SOUTH CHINA AGRICULT 2015-05-20 — — CN disclosed
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES AG (AT) 2014-11-27 — — US disclosed
EP-2674161-A1 FMO3 inhibitors for treating pain Akron Molecules GmbH (AT) 2013-12-18 — — EP disclosed
US-20130252924-A1 Compounds and Methods for Treating Pain AKRON MOLECULES GMBH (AT) 2013-09-26 — — US disclosed
EP-2637649-A2 COMPOUNDS AND METHODS FOR TREATING PAIN Akron Molecules GmbH (AT) 2013-09-18 — — EP disclosed
WO-2012062925-A2 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES GMBH (AT) 2012-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN TRPV1, ACHE, OPRL1 MEN1 3678/4885KMT2A 2963/4885HTR2B 324/4885
US-20160333031-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 MEN1 3937/4885KMT2A 2813/4885HTR2B 4133/4885
US-20230242557-A9 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 MEN1 3937/4885KMT2A 2813/4885HTR2B 4133/4885
US-11560385-B2 Proteasome activity enhancing compounds PSMG3, PSME3, PSMC4 MEN1 4126/4885KMT2A 3433/4885HTR2B 3016/4885
US-12319698-B2 Proteasome activity enhancing compounds PSMG3, PSME3, PSMC4 MEN1 4126/4885KMT2A 3433/4885HTR2B 3016/4885
US-20220298181-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSMB1, PSMC1 MEN1 3937/4885KMT2A 2813/4885HTR2B 4133/4885
US-20130252924-A1 Compounds and Methods for Treating Pain TRPV1, ACHE, OPRL1 MEN1 3678/4885KMT2A 2963/4885HTR2B 324/4885
US-11242361-B2 Proteasome activity enhancing compounds PSMG3, PSMB1, PSMC1 MEN1 3937/4885KMT2A 2813/4885HTR2B 4133/4885
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSME3, PSMC4 MEN1 4126/4885KMT2A 3433/4885HTR2B 3016/4885
US-11958873-B2 Proteasome activity enhancing compounds PSMG3, PSMB1, PSMC1 MEN1 3937/4885KMT2A 2813/4885HTR2B 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.